開拓藥業(09939.HK)與仁東醫學、惠每健康簽署戰略合作協議 打造診療一體化平台
開拓藥業(09939.HK)與仁東醫學、惠每健康簽署戰略合作框架協議,三方將推進戰略合作,旨在打造診療一體化平台和以患者為中心的閉環營銷體系,積極推動前列腺癌、乳腺癌等腫瘤患者的伴隨診斷,以及大數據分析、患者管理、新藥研發和數字化營銷等一體化平台建設。
公司指,仁東醫學是中國領先的基因檢測整體解決方案供應商,是國內泌尿系統腫瘤精准檢測的市場領導者;惠每健康是Mayo Clinic和高瓴資本在中國的合資公司惠每醫療集團的子公司,專注於基於SaaS平台提供一站式賦能學術營銷解決方案,致力於成為中國醫療數字化營銷領先者。此次合作以前列腺癌領域開啟,後續在乳腺癌等多癌症領域鋪開,實現三方共同的戰略延伸。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.